Skip to main content
Back to companies
Boulder, Colorado, United StatesFounded 201967+ employeesELVN
$460M raisedIPO· last: post ipo equity (Jun 2025)· 5 rounds
Backed by(14 investors)
Surveyor Capital · LeadCormorant Asset Management · Lead+11 more

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.

Founders

Skip jobs list

Open Positions at Enliven Therapeutics (0 Jobs)

No open positions at the moment.
Try adjusting your filters or browse all jobs
Browse All Jobs